{"abstract": "A deal with Pfizer would have been one of the biggest ever in the pharmaceutical industry. But whether such a deal makes sense is another matter.", "web_url": "https://dealbook.nytimes.com/2014/04/21/spurning-merger-approaches-astrazeneca-pursues-own-path/", "snippet": "A deal with Pfizer would have been one of the biggest ever in the pharmaceutical industry. But whether such a deal makes sense is another matter.", "lead_paragraph": "The British drug company AstraZeneca said no to a tie-up with Pfizer, turning down the possibility of one of the biggest drug mergers in recent history. ", "source": "The New York Times", "multimedia": [{"rank": 0, "subtype": "xlarge", "caption": null, "credit": null, "type": "image", "url": "images/2014/04/22/business/dbpix-drug2/dbpix-drug2-articleLarge.jpg", "height": 400, "width": 600, "subType": "xlarge", "crop_name": "articleLarge", "legacy": {"xlarge": "images/2014/04/22/business/dbpix-drug2/dbpix-drug2-articleLarge.jpg", "xlargewidth": 600, "xlargeheight": 400}}, {"rank": 0, "subtype": "jumbo", "caption": null, "credit": null, "type": "image", "url": "images/2014/04/22/business/dbpix-drug2/dbpix-drug2-jumbo.jpg", "height": 682, "width": 1024, "subType": "jumbo", "crop_name": "jumbo", "legacy": {}}, {"rank": 0, "subtype": "superJumbo", "caption": null, "credit": null, "type": "image", "url": "images/2014/04/22/business/dbpix-drug2/dbpix-drug2-superJumbo.jpg", "height": 1365, "width": 2048, "subType": "superJumbo", "crop_name": "superJumbo", "legacy": {}}, {"rank": 0, "subtype": "thumbnail", "caption": null, "credit": null, "type": "image", "url": "images/2014/04/22/business/dbpix-drug2/dbpix-drug2-thumbStandard.jpg", "height": 75, "width": 75, "subType": "thumbnail", "crop_name": "thumbStandard", "legacy": {"thumbnail": "images/2014/04/22/business/dbpix-drug2/dbpix-drug2-thumbStandard.jpg", "thumbnailwidth": 75, "thumbnailheight": 75}}, {"rank": 0, "subtype": "thumbLarge", "caption": null, "credit": null, "type": "image", "url": "images/2014/04/22/business/dbpix-drug2/dbpix-drug2-thumbLarge.jpg", "height": 150, "width": 150, "subType": "thumbLarge", "crop_name": "thumbLarge", "legacy": {}}], "headline": {"main": "Spurning Merger Approaches, AstraZeneca Pursues Own Path", "kicker": "DealBook", "content_kicker": null, "print_headline": "", "name": null, "seo": null, "sub": null}, "keywords": [{"name": "subject", "value": "Drugs (Pharmaceuticals)", "rank": 1, "major": "N"}, {"name": "subject", "value": "Mergers, Acquisitions and Divestitures", "rank": 2, "major": "N"}, {"name": "persons", "value": "Soriot, Pascal", "rank": 3, "major": "N"}, {"name": "organizations", "value": "AstraZeneca PLC", "rank": 4, "major": "N"}, {"name": "organizations", "value": "Pfizer Inc", "rank": 5, "major": "N"}, {"name": "organizations", "value": "Roche Holding AG", "rank": 6, "major": "N"}, {"name": "organizations", "value": "Warner-Lambert Co", "rank": 7, "major": "N"}], "pub_date": "2014-04-21T17:17:13+0000", "document_type": "article", "news_desk": "Business", "section_name": "Business Day", "byline": {"original": "By Michael J. de la Merced and Andrew Pollack", "person": [{"firstname": "Michael", "middlename": "J.", "lastname": "de la Merced", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}, {"firstname": "Andrew", "middlename": null, "lastname": "Pollack", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 2}], "organization": null}, "type_of_material": "News", "_id": "nyt://article/4ce50f9c-f4d3-55e9-ad7b-d1b50b6cd6c3", "word_count": 976, "uri": "nyt://article/4ce50f9c-f4d3-55e9-ad7b-d1b50b6cd6c3"}